SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Retina
Autores principales: Avery, Robert L., Castellarin, Alessandro A., Steinle, Nathan C., Dhoot, Dilsher S., Pieramici, Dante J., See, Robert, Couvillion, Stephen, Nasir, Ma'an A., Rabena, Melvin D., Maia, Mauricio, Van Everen, Sherri, Le, Kha, Hanley, William D.
Formato: Artigo
Lenguaje:Inglês
Publicado: Retina 2017
Materias:
Original Study
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642319/
https://ncbi.nlm.nih.gov/pubmed/28106709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IAE.0000000000001493
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares